Biolex taps Cook Pharmica to manufacture Locteron for phase-3 trials (and presumably for commercialization if the phase-3 trials are successful): <a href="http://finance.yahoo.com/news/Biolex-Therapeutics-Selects-iw-3953994604.html?x=0&.v=1" rel="nofollow" target="_blank">http://finance.yahoo.com/news/Biolex-Therapeutics-Selects-iw-3953994604.html?x=0&.v=1</a> Locteron is a long-acting interferon alpha for HCV derived from transgenic plants.